Clinical Trial Update: Phase 1 Safety Testing of SAR405838 [Phase 1]

View source ↗

Summary

Sanofi's Phase 1 safety study of the cancer drug SAR405838 has completed, evaluating initial safety in patients with malignant neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SAR405838 (SAR405838)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED